A Phase 1 interventional study of Alendronate and Enlicitide Decanoate in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-18.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to a single dose of alendronate over time in a healthy participant's body when the participant is given a single dose of enlicitide decanoate. Researchers want to learn how safe and tolerable is the co-administration of enlicitide decanoate and alendronate.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single oral dose of alendronate on Day 1 OR participants receive a single oral dose of alendronate on Day 15 depending on randomization.
Drug: Alendronate
Participants receive an oral dose of alendronate plus an oral dose of enlicitide decanoate on Day 1 OR participants receive an oral dose of alendronate plus an oral dose of enlicitide decanoate on Day 15 depending on randomization.
Drug: Alendronate · Drug: Enlicitide Decanoate
Oral administration
Also known as: Fosamax®
Oral administration
Also known as: MK-0616
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Alendronate
Blood samples will be collected to determine the AUC0-Last of alendronate.
Time frame: At designated timepoints (up to approximately 10 hours post-dose)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Alendronate
Blood samples will be collected to determine the AUC0-Inf of alendronate.
Time frame: At designated timepoints (up to approximately 10 hours post-dose)
Maximum Plasma Concentration (Cmax) of Alendronate
Blood samples will be collected to determine the Cmax of alendronate.
Time frame: At designated timepoints (up to approximately 10 hours post-dose)
Time to Maximum Plasma Concentration (Tmax) of Alendronate
Blood samples will be collected to determine the Tmax of alendronate.
Time frame: At designated timepoints (up to approximately 10 hours post-dose)
Apparent Terminal Half-Life (t1/2) of Alendronate
Blood samples will be collected to determine the t1/2 of alendronate.
Time frame: At designated timepoints (up to approximately 10 hours post-dose)
Apparent Clearance (CL/F) of Alendronate
Blood samples will be collected to determine the CL/F of alendronate.
Time frame: At designated timepoints (up to approximately 10 hours post-dose)
Apparent Volume of Distribution (Vz/F) of Alendronate
Blood samples will be collected to determine Vz/F of alendronate.
Time frame: At designated timepoints (up to approximately 10 hours post-dose)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 8 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 3 weeks
Total Amount of Alendronate Excreted Unchanged Over a Period of 48 Hours (Ae0-48) after Alendronate Administration
Urine samples will be collected to determine the Ae0-48 of alendronate.
Time frame: At designated timepoints (up to approximately 48 hours post-dose)
Maximum Rate (Rmax) of Alendronate Excretion
Urine samples will be collected to determine the Rmax of alendronate excretion.
Time frame: At designated timepoints (up to approximately 48 hours post-dose)
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Apr 2024 to primary completion in Jun 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alendronate · MK-0616